Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer

Area of Science:

• Cancer Biology
• Genomics
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) are effective against cancers with specific mutations.
• Clinical response to TKIs is often limited by the development of drug resistance.
• Cancer cells can exhibit heterogeneity, leading to differential responses to therapy.

Purpose of the Study:

• To investigate the existence and characteristics of cancer cell subpopulations.
• To identify molecular mechanisms underlying drug tolerance in cancer cells.
• To explore combination therapies targeting drug-tolerant cancer cell populations.

Main Methods:

• Single-cell RNA sequencing (scRNA-seq) was employed to analyze cancer cell heterogeneity.
• Analysis of differentially expressed genes in drug-tolerant versus drug-sensitive populations.
• Utilized the LINCS database for prediction and validation of small molecules targeting tolerant cells.

Main Results:

• Identified multiple cancer cell subpopulations with distinct epigenetic profiles and sensitivities.
• Genes involved in epithelial-to-mesenchymal transition, drug metabolism, and cholesterol homeostasis were upregulated in tolerant cells.
• Crizotinib, in combination with EGFR inhibitors, demonstrated efficacy in inhibiting specific EGFR inhibitor-tolerant clones.

Conclusions:

• Cancer drug tolerance is mediated by distinct, epigenetically altered cell subpopulations.
• Combination therapies targeting these specific tolerant subpopulations show promise for overcoming resistance.
• This study provides insights into the spectrum of changes associated with drug tolerance and potential therapeutic strategies.